Upcoming adjustments to Medicare services in the year 2026
The Inflation Reduction Act (IRA) of 2022 has brought significant changes to the Medicare Prescription Drug Program (Part D), affecting millions of beneficiaries.
One of the key impacts is the capping of out-of-pocket costs for Medicare Part D beneficiaries at $2,000 annually, starting in 2025. This cap will rise yearly with inflation, providing financial relief to about 11 million enrollees who previously faced unlimited costs.
Another significant change is the introduction of Medicare's ability to negotiate drug prices for certain high-cost medications, with the first negotiations taking effect in 2026. These negotiations aim to lower drug costs and are expected to save the government billions over the next decade.
Drug manufacturers will also be required to pay inflation rebates to Medicare if they raise prices faster than inflation, helping to control drug price hikes.
Parts of Medicare Part D coverage have been improved, including providing insulin for no more than $35 per month and offering recommended vaccines for free, enhancing affordability.
To stabilise premiums amid these changes, the Centers for Medicare & Medicaid Services (CMS) has introduced a Part D Premium Stabilization Demonstration, starting in 2025. This aims to limit premium increases to no more than $35 and provide subsidies, reducing disruptive enrollment shifts and premium volatility.
However, the IRA also imposes a nine-year ban on expanding Medicare Savings Programs (MSPs), which help low-income beneficiaries with premiums and out-of-pocket costs. This is expected to prevent some eligible beneficiaries from accessing additional financial support.
Looking ahead to the next Medicare open enrollment under the new administration in 2025 and beyond, changes are expected in Medicare Advantage (Part C) enrolment, with plans offering more supplemental benefits but facing increased scrutiny to control costs and improve transparency. Part D plans are also adjusting formularies, cost-sharing designs, and premiums within the limits set by CMS's stabilization efforts.
The administration and CMS are expected to continue emphasising improving price transparency and accountability of Medicare plans while balancing premium stability and coverage enhancements.
Other changes include the annual deductible for Medicare Part D insurance increasing to up to $615 for 2026, an increase of $25 over the 2022 amount of $590. Prior authorisations for traditional Medicare will be implemented in six states starting from January 1, 2026, with a human being reviewing the information for prior authorisation decisions, not AI.
It is important for Medicare beneficiaries to check their coverage each year as costs, benefits, and providers can change annually. Unbiased help for reviewing Medicare Advantage plans can be found through the State Health Insurance Assistance Program (SHIP) in your state.
In addition, if traveling outside of the country, it is recommended to consult the CDC's list of recommended vaccinations depending on the destination, as there is a global Measles outbreak.
Sources:
- Kaiser Family Foundation
- AARP
- Modern Healthcare
- CMS
Mining the text for references to science and health-related topics, we find that the Inflation Reduction Act (IRA) includes provisions for lowering drug costs in Medicare Part D, a medical insurance program for seniors. Science is involved in the negotiations over drug prices and the setting of inflation caps, with the aim of providing health-and-wellness benefits to beneficiaries and controlling healthcare expenditures. Additionally, the Act imposes medical-conditions related requirements on drug manufacturers, such as inflating rebates if prices increase faster than inflation, and also bans expanding Medicare Savings Programs (MSPs) for nine years, which might affect the overall healthcare coverage of low-income beneficiaries.
